Poor
Not Aligned
Patient Risk:
Low
Summary
Only 3 of 12 evaluated claims are supported by the provided FDA label (brand/ingredient and general osteoporosis use). The remaining claims concern “generic/biosimilar” availability, regulatory timing, and a specific tracking service, none of which are supported or addressed in the supplied label excerpts.
Category Scores
Accurate Statements
Forteo is the brand name for teriparatide.
Supported by label section 11 DESCRIPTION.
Teriparatide is a hormone (parathyroid hormone).
Supported by label section 11 DESCRIPTION (recombinant human parathyroid hormone analog).
Teriparatide is used for certain osteoporosis patients.
Supported by label section 1 INDICATIONS AND USAGE (multiple osteoporosis populations).
Unsupported Statements
The commonly sought "Forteo generic" is a teriparatide injection made by another manufacturer.
Not addressed in the provided label sections (no statements about generics, interchangeable products, or manufacturers).
FDA generics are not always available as simple "generic drugs" for biologic-like complex products.
Not addressed in the provided label sections.
FDA generics may be delayed or unavailable where patents or exclusivity still apply.
Not addressed in the provided label sections.
People usually mean a different manufacturer’s teriparatide injection when they search for a "Forteo generic".
Not addressed in the provided label sections.
People usually mean a biosimilar or related follow-on product if one exists in the market for that specific product category.
Not addressed in the provided label sections.
An accurate, up-to-date answer on what’s currently available under the "generic Forteo" name requires knowing the market (U.S., Canada, EU, etc.).
Not addressed in the provided label sections.
An accurate, up-to-date answer on what’s currently available under the "generic Forteo" name requires knowing whether you’re looking for FDA-approved equivalents.
Not addressed in the provided label sections.
Generic entry can be delayed by patents and exclusivity.
Not addressed in the provided label sections.
DrugPatentWatch.com tracks relevant intellectual property for Forteo.
Not addressed in the provided label sections (no mention of this service).
Contradictions
Important Omissions
No omissions are identifiable relative to a specific label-supported question, because the evaluated claims are primarily outside labeling content (generic/biosimilar availability and third-party tracking) rather than drug-specific prescribing details.
Importance:
Low
Safety Assessment
Potential Patient Risk:
Low
The unsupported claims concern product availability/terminology and an external tracking service, not dosing, contraindications, boxed warnings, or safety instructions from the provided label.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Most claims are not supported by the supplied FDA label excerpts and instead address generic/biosimilar availability concepts and a specific third-party site that the label does not mention.
Suggested Improvement
Limit statements to label-supported prescribing information (e.g., indication and description) and remove or qualify any assertions about “Forteo generic,” biosimilar/follow-on availability, patent/exclusivity timing, market-specific availability, or DrugPatentWatch.com unless directly supported by the provided labeling.